IL138637A0 - (4-arylsulfonylamino) tetrahydropyran-4- carboxylic acid hydroxamides - Google Patents

(4-arylsulfonylamino) tetrahydropyran-4- carboxylic acid hydroxamides

Info

Publication number
IL138637A0
IL138637A0 IL13863799A IL13863799A IL138637A0 IL 138637 A0 IL138637 A0 IL 138637A0 IL 13863799 A IL13863799 A IL 13863799A IL 13863799 A IL13863799 A IL 13863799A IL 138637 A0 IL138637 A0 IL 138637A0
Authority
IL
Israel
Prior art keywords
arylsulfonylamino
tetrahydropyran
carboxylic acid
acid hydroxamides
hydroxamides
Prior art date
Application number
IL13863799A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL138637A0 publication Critical patent/IL138637A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
IL13863799A 1998-04-10 1999-03-24 (4-arylsulfonylamino) tetrahydropyran-4- carboxylic acid hydroxamides IL138637A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8136498P 1998-04-10 1998-04-10
PCT/IB1999/000505 WO1999052889A1 (en) 1998-04-10 1999-03-24 (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides

Publications (1)

Publication Number Publication Date
IL138637A0 true IL138637A0 (en) 2001-10-31

Family

ID=22163679

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13863799A IL138637A0 (en) 1998-04-10 1999-03-24 (4-arylsulfonylamino) tetrahydropyran-4- carboxylic acid hydroxamides

Country Status (42)

Country Link
US (1) US6087392A (es)
EP (1) EP1070058B1 (es)
JP (1) JP3660873B2 (es)
KR (1) KR100430183B1 (es)
CN (1) CN1296481A (es)
AP (1) AP968A (es)
AR (1) AR019263A1 (es)
AT (1) ATE239005T1 (es)
AU (1) AU758701B2 (es)
BG (1) BG104917A (es)
BR (1) BR9909562A (es)
CA (1) CA2327758C (es)
CO (1) CO5050369A1 (es)
CZ (1) CZ20003737A3 (es)
DE (1) DE69907435T2 (es)
DK (1) DK1070058T3 (es)
DZ (1) DZ2753A1 (es)
EA (1) EA004227B1 (es)
ES (1) ES2192397T3 (es)
GT (1) GT199900043A (es)
HR (1) HRP20000648A2 (es)
HU (1) HUP0101613A3 (es)
ID (1) ID26222A (es)
IL (1) IL138637A0 (es)
IS (1) IS5619A (es)
MA (1) MA24832A1 (es)
MY (1) MY132929A (es)
NO (1) NO20005076L (es)
NZ (1) NZ506806A (es)
OA (1) OA11498A (es)
PA (1) PA8469501A1 (es)
PE (1) PE20000414A1 (es)
PL (1) PL343518A1 (es)
PT (1) PT1070058E (es)
SA (1) SA99200091A (es)
SK (1) SK284154B6 (es)
TN (1) TNSN99053A1 (es)
TR (1) TR200002951T2 (es)
UA (1) UA55526C2 (es)
WO (1) WO1999052889A1 (es)
YU (1) YU57500A (es)
ZA (1) ZA992629B (es)

Families Citing this family (296)

* Cited by examiner, โ€  Cited by third party
Publication number Priority date Publication date Assignee Title
SG72752A1 (en) * 1996-10-31 2000-05-23 Hitachi Chemical Co Ltd Heat resistant resin composition and adhesive sheet using the same
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
CN1113862C (zh) * 1997-02-03 2003-07-09 ่พ‰็‘žไบงๅ“ๅ…ฌๅธ ่ŠณๅŸบ็ฃบ้…ฐๆฐจๅŸบๅผ‚็พŸ่‚Ÿ้…ธ่ก็”Ÿ็‰ฉ
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
US20030225150A1 (en) * 1997-04-21 2003-12-04 Pharmacia Corporation Method of using a COX-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US20030203956A1 (en) * 1998-12-23 2003-10-30 Masterrer Jaime L. Method of using a cyclooxygenase-2 inhibitor and one or more ornithine decarboxylase inhibitors as a combination therapy in the treatment of neoplasia
US20040053900A1 (en) * 1998-12-23 2004-03-18 Pharmacia Corporation Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US20030013739A1 (en) * 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
US20020103141A1 (en) * 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer
US20030119895A1 (en) * 1998-12-23 2003-06-26 Pharmacia Corporation Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia
ATE254119T1 (de) * 1999-05-28 2003-11-15 Pfizer Prod Inc 3-(arylsulfonylamino)-tetrahydropyran-3- carbonsรคure hydroxamide
IL138686A0 (en) * 1999-10-01 2001-10-31 Pfizer Prod Inc ฮฑ- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS
EP2289549A3 (en) 1999-10-01 2011-06-15 Immunogen, Inc. Immunoconjugates for treating cancer
UA74803C2 (uk) 1999-11-11 2006-02-15 ะžัั– ะคะฐั€ะผะฐััŒัŽั‚ั–ะบะฐะปะท, ะ†ะฝะบ. ะกั‚ั–ะนะบะธะน ะฟะพะปั–ะผะพั€ั„ ะณั–ะดั€ะพั…ะปะพั€ะธะดัƒ n-(3-ะตั‚ะธะฝั–ะปั„ะตะฝั–ะป)-6,7-ะฑั–ั(2-ะผะตั‚ะพะบัั–ะตั‚ะพะบัะธ)-4-ั…ั–ะฝะฐะทะพะปั–ะฝะฐะผั–ะฝัƒ, ัะฟะพัั–ะฑ ะนะพะณะพ ะพะดะตั€ะถะฐะฝะฝั (ะฒะฐั€ั–ะฐะฝั‚ะธ) ั‚ะฐ ั„ะฐั€ะผะฐั†ะตะฒั‚ะธั‡ะฝะต ะทะฐัั‚ะพััƒะฒะฐะฝะฝั
AU2001239791A1 (en) * 2000-02-17 2001-08-27 Du Pont Pharmaceuticals Company Succinoylamino carbocycles and heterocycles as inhibitors of abeta protein production
BR0109328A (pt) * 2000-03-21 2003-06-10 Procter & Gamble Inibidores de metaloprotease n-substituรฌdos, contendo cadeia lateral heterocรฌclica
MXPA02009312A (es) * 2000-03-21 2003-03-12 Procter & Gamble Inhibidores de las metaloproteasas que contienen cadenas laterales heterociclicas.
IL151250A0 (en) 2000-03-21 2003-04-10 Procter & Gamble Difluorobutyric acid metalloprotease inhibitors
EP1138680A1 (en) * 2000-03-29 2001-10-04 Pfizer Products Inc. Gem substituted sulfonyl hydroxamic acids as MMP inhibitors
US6436629B1 (en) * 2000-10-27 2002-08-20 The Regents Of The University Of California Modulating angiogenesis
PE20020801A1 (es) 2001-01-05 2002-09-06 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
JP2004527568A (ja) * 2001-05-03 2004-09-09 ใ‚จใƒ•๏ผŽใƒ›ใƒ•ใƒžใƒณโˆ’ใƒฉใ€€ใƒญใ‚ทใƒฅใ€€ใ‚ขใƒผใ‚ฒใƒผ ใ‚ผใƒฉใƒใƒŠใƒผใ‚ผใ‚คใƒณใƒ’ใƒ“ใ‚ฟใƒผใจๆŠ—่…ซ็˜ๅ‰คใจใฎ็ต„ใฟๅˆใ‚ใ›ใ€ใŠใ‚ˆใณใใฎไฝฟ็”จ
AU2002345792A1 (en) 2001-06-21 2003-01-08 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
US6607550B1 (en) 2001-09-06 2003-08-19 Anodyne Therapeutics, L.L.C. Method of treating neuropathy using a photo energy device
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP1466899A4 (en) * 2001-12-27 2010-01-06 Dainippon Sumitomo Pharma Co "HYDROXAMIC ACID DERIVATIVE AND MMP INHIBITOR CONTAINING THEM AS AN ACTIVE SUBSTANCE"
DE10206404A1 (de) * 2002-02-14 2003-08-28 Gruenenthal Gmbh Synthese von substituierten Sulfonylaminen
EP1483268A2 (en) 2002-03-01 2004-12-08 Pfizer Inc. Indolyl-urea derivatives of thienopyridines useful as anti-angiogenic agents
AR038971A1 (es) 2002-03-13 2005-02-02 Array Biopharma Inc Derivados de bencimidazol n3 alquilado como inhibidores de mek
PL374117A1 (en) 2002-05-29 2005-10-03 Merck & Co, Inc. Compounds useful in the treatment of anthrax and inhibiting lethal factor
UA77303C2 (en) 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
RS20050430A (en) 2002-12-19 2007-08-03 Pfizer Inc., 2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases
BRPI0407827B8 (pt) 2003-02-26 2021-05-25 Sugen Inc compostos de aminoeteroarila como inibidores de proteรญna cinase e respectivos usos
US20040215335A1 (en) * 2003-04-25 2004-10-28 Brin David S. Methods and apparatus for treatment of aneurysmal tissue
WO2004106319A1 (en) * 2003-05-30 2004-12-09 Pfizer Products Inc. Crystal forms of 4-[4-(4-fluorophenoxy)benzenesulfonylamino]-tetrahydropyran-4-carboxylic acid hydroxyamide
GB0319069D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Therapeutically useful compounds
US20050107350A1 (en) * 2003-08-22 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
WO2005021554A1 (en) 2003-08-29 2005-03-10 Pfizer Inc. Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
PT2251327E (pt) 2003-11-19 2014-03-04 Array Biopharma Inc Inibidores heterocรญclicos de mek
WO2005051919A1 (en) * 2003-11-26 2005-06-09 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
CN1950354A (zh) 2004-05-11 2007-04-18 ้ป˜ๅ…‹ๅ…ฌๅธ N๏ผ็ฃบ้…ฐๅŒ–๏ผๆฐจๅŸบ้…ธ่ก็”Ÿ็‰ฉ็š„ๅˆถๅค‡ๆ–นๆณ•
PL1786785T3 (pl) 2004-08-26 2010-08-31 Pfizer Enancjomerycznie czyste zwiฤ…zki aminoheteroarylowe jako kinazy biaล‚kowe
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
US7429667B2 (en) 2005-01-20 2008-09-30 Ardea Biosciences, Inc. Phenylamino isothiazole carboxamidines as MEK inhibitors
CN102304086B (zh) 2005-05-18 2013-12-04 ้˜ตๅˆ—็”Ÿ็‰ฉๅˆถ่ฏๅ…ฌๅธ Mek็š„ๆ‚็ŽฏๆŠ‘ๅˆถๅ‰‚ๅŠๅ…ถไฝฟ็”จๆ–นๆณ•
US7820664B2 (en) 2007-01-19 2010-10-26 Bayer Schering Pharma Ag Inhibitors of MEK
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
ES2374450T3 (es) 2005-09-20 2012-02-16 OSI Pharmaceuticals, LLC Marcadores biolรณgicos predictivos de respuesta anticancerรญgena para inhibidores de cinasa del receptor del factor de crecimiento 1 similar a insulina.
TWI405756B (zh) 2005-12-21 2013-08-21 Array Biopharma Inc ๆ–ฐ็ฉŽ็กซ้…ธๆฐซ้นฝ
EP1986652B1 (en) * 2006-02-15 2013-03-20 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
US7842836B2 (en) 2006-04-11 2010-11-30 Ardea Biosciences N-aryl-N'alkyl sulfamides as MEK inhibitors
EP2012786B1 (en) 2006-04-18 2010-10-06 Ardea Biosciences, Inc. Pyridone sulfonamides and pyridone sulfamides as mek inhibitors
CA2652367A1 (en) * 2006-05-16 2007-11-29 Merck & Co., Inc. Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
US8404783B2 (en) * 2006-07-12 2013-03-26 Novartis Ag Polymers
JP2010513263A (ja) 2006-12-15 2010-04-30 ใƒ•ใ‚กใ‚คใ‚ถใƒผใƒปใƒ—ใƒญใƒ€ใ‚ฏใƒ„ใƒปใ‚คใƒณใ‚ฏ ใƒ™ใƒณใ‚บใ‚คใƒŸใƒ€ใ‚พใƒผใƒซ่ช˜ๅฐŽไฝ“
JP4782239B2 (ja) 2007-04-18 2011-09-28 ใƒ•ใ‚กใ‚คใ‚ถใƒผใƒปใƒ—ใƒญใƒ€ใ‚ฏใƒ„ใƒปใ‚คใƒณใ‚ฏ ็•ฐๅธธ็ดฐ่ƒžๅข—ๆฎ–ๆฒป็™‚ใฎใŸใ‚ใฎใ‚นใƒซใƒ›ใƒ‹ใƒซใ‚ขใƒŸใƒ‰่ช˜ๅฐŽไฝ“
US8530463B2 (en) 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
CA2694646C (en) 2007-07-30 2017-09-05 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
JP2011517313A (ja) 2007-12-11 2011-06-02 ใƒ“ใ‚ขใƒกใƒˆ ใƒ•ใ‚กใƒผใƒžใ‚ทใƒฅใƒผใƒ†ใ‚ฃใ‚ซใƒซใ‚บ๏ผŒใ‚คใƒณใ‚ฏ๏ผŽ ้‡‘ๅฑž็ตๅˆ้ƒจๅˆ†ใ‚’ๆจ™็š„ๅŒ–้ƒจๅˆ†ใจ็ต„ใฟๅˆใ‚ใ›ใฆไฝฟ็”จใ™ใ‚‹้‡‘ๅฑž้…ต็ด ้˜ปๅฎณๅ‰ค
DK2222675T3 (da) 2007-12-19 2013-11-04 Genentech Inc 5-anilinoimidazopyridiner og fremgangsmรฅder til deres anvendelse
JP5710269B2 (ja) 2007-12-21 2015-04-30 ใ‚ธใ‚งใƒใƒณใƒ†ใƒƒใ‚ฏ๏ผŒ ใ‚คใƒณใ‚ณใƒผใƒใƒฌใ‚คใƒ†ใƒƒใƒ‰ ใ‚ขใ‚ถใ‚คใƒณใƒ‰ใƒชใ‚ธใƒณ้กžใจไฝฟ็”จๆ–นๆณ•
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
SG10201605472WA (en) 2008-01-04 2016-09-29 Intellikine Llc Certain Chemical Entities, Compositions And Methods
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
US8895546B2 (en) 2009-03-27 2014-11-25 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
US20090258865A1 (en) 2008-03-28 2009-10-15 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
KR20110039326A (ko) 2008-07-08 2011-04-15 ์ธํ…”๋ฆฌ์นด์ธ, ์ธํฌ. ํ‚ค๋‚˜์ œ ์–ต์ œ์ œ ๋ฐ ์‚ฌ์šฉ ๋ฐฉ๋ฒ•
JP5836125B2 (ja) 2008-10-16 2015-12-24 ใƒฆใƒ‹ใƒใƒผใ‚ทใƒ†ใ‚ฃ ใ‚ชใƒ– ใƒ”ใƒƒใƒ„ใƒใƒผใ‚ฐ โˆ’ ใ‚ชใƒ– ใ‚ถ ใ‚ณใƒขใƒณใ‚ฆใ‚งใƒซใ‚น ใ‚ทใ‚นใƒ†ใƒ  ใ‚ชใƒ– ใƒใ‚คใƒคใƒผ ใ‚จใƒ‡ใƒฅใ‚ฑใ‚คใ‚ทใƒงใƒณ ้ซ˜ๅˆ†ๅญ้‡ใƒกใƒฉใƒŽใƒผใƒž้–ข้€ฃๆŠ—ๅŽŸใซๅฏพใ™ใ‚‹ๅฎŒๅ…จใƒ’ใƒˆๆŠ—ไฝ“ใŠใ‚ˆใณใใฎไฝฟ็”จ
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
JO2870B1 (en) * 2008-11-13 2015-03-15 ู…ูŠุฑูƒ ุดุงุฑุจ ุงู†ุฏ ุฏูˆู‡ู… ูƒูˆุฑุจ Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
DK2385938T3 (en) * 2009-01-12 2015-04-27 Pfizer Ltd Sulfonamidderivater
NZ594177A (en) 2009-02-05 2014-02-28 Immunogen Inc Novel benzodiazepine derivatives
EP2393814A1 (en) 2009-02-09 2011-12-14 SuperGen, Inc. Pyrrolopyrimidinyl axl kinase inhibitors
EP2400985A2 (en) 2009-02-25 2012-01-04 OSI Pharmaceuticals, LLC Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
JP2012519170A (ja) 2009-02-26 2012-08-23 ใ‚ชใƒผใ‚จใ‚นใ‚ขใ‚คใƒปใƒ•ใ‚กใƒผใƒžใ‚ทใƒฅใƒผใƒ†ใ‚ฃใ‚ซใƒซใ‚บ๏ผŒใ‚จใƒซใ‚จใƒซใ‚ทใƒผ ็”Ÿไฝ“ๅ†…ใฎ่…ซ็˜็ดฐ่ƒžใฎ๏ฝ…๏ฝ๏ฝ”ใ‚นใƒ†ใƒผใ‚ฟใ‚นใ‚’ใƒขใƒ‹ใ‚ฟใƒผใ™ใ‚‹ใŸใ‚ใฎ๏ฝ‰๏ฝŽ๏ฝ“๏ฝ‰๏ฝ”๏ฝ•ๆณ•
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
TW201035088A (en) 2009-02-27 2010-10-01 Supergen Inc Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401613A2 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
CN106478496A (zh) 2009-03-27 2017-03-08 ้˜ฟ่ฟช็”Ÿ็‰ฉ็ง‘ๅญฆๅ…ฌๅธ ไฝœไธบmekๆŠ‘ๅˆถๅ‰‚็š„ไบŒๆฐขๅกๅ•ถ็ฃบ้…ฐ่ƒบๅ’ŒไบŒๆฐขๅกๅ•ถ็กซ้…ฐ่ƒบ
EP2427195B1 (en) 2009-05-07 2019-05-01 Intellikine, LLC Heterocyclic compounds and uses thereof
WO2011014726A1 (en) 2009-07-31 2011-02-03 Osi Pharmaceuticals, Inc. Mtor inhibitor and angiogenesis inhibitor combination therapy
CA2771532C (en) 2009-08-17 2021-03-23 Intellikine, Inc. Heterocyclic compounds and uses thereof
JP2013503846A (ja) 2009-09-01 2013-02-04 ใƒ•ใ‚กใ‚คใ‚ถใƒผใƒปใ‚คใƒณใ‚ฏ ใƒ™ใƒณใ‚บใ‚คใƒŸใƒ€ใ‚พใƒผใƒซ่ช˜ๅฐŽไฝ“
KR20120092096A (ko) 2009-09-02 2012-08-20 ๋จธํฌ ์ƒคํ”„ ์•ค๋“œ ๋” ์ฝ”ํฌ๋ ˆ์ด์…˜ ๋‹น๋‡จ๋ณ‘์˜ ์น˜๋ฃŒ ๋˜๋Š” ์˜ˆ๋ฐฉ์„ ์œ„ํ•œ ๋””ํŽฉํ‹ฐ๋”œ ํŽฉํ‹ฐ๋‹ค์ œ-๏ฝ‰๏ฝ– ์–ต์ œ์ œ๋กœ์„œ์˜ ์•„๋ฏธ๋…ธํ…ŒํŠธ๋ผํžˆ๋“œ๋กœํ”ผ๋ž€
WO2011037793A1 (en) 2009-09-25 2011-03-31 Merck Sharp & Dohme Corp. Substituted aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
ES2534358T3 (es) 2009-10-13 2015-04-21 Allomek Therapeutics, Llc Inhibidores novedosos de MEK รบtiles en el tratamiento de enfermedades
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
SG10201500895XA (en) 2009-11-05 2015-04-29 Rhizen Pharmaceuticals Sa Chromen-4-one Derivatives As Kinase Modulators
AU2011215900A1 (en) 2010-02-10 2012-07-26 Immunogen, Inc. CD20 antibodies and uses thereof
MX343383B (es) 2010-02-12 2016-11-03 Pfizer Inc * Sales y polimorfos de 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3, 4,5-tetrahidro-6h-acepino[5,4,3-cd]indol-6-ona.
US20110275644A1 (en) 2010-03-03 2011-11-10 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2011109584A2 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CN103068824B (zh) 2010-05-17 2017-09-08 ๅฐ่”ป็œŸๆฒป็–—ๅ…ฌๅธ ไฝœไธบ่›‹็™ฝๆฟ€้…ถ่ฐƒ่Š‚ๅ‰‚็š„ๆ–ฐๅž‹3,5โ€‘ไบŒๅ–ไปฃโ€‘3hโ€‘ๅ’ชๅ”‘ๅนถ[4,5โ€‘b]ๅกๅ•ถๅ’Œ3,5โ€‘ไบŒๅ–ไปฃโ€‘3hโ€‘[1,2,3]***ๅนถ[4,5โ€‘b]ๅกๅ•ถๅŒ–ๅˆ็‰ฉ
WO2011146882A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
EP2582727B8 (en) 2010-06-16 2017-04-19 University of Pittsburgh- Of the Commonwealth System of Higher Education Antibodies to endoplasmin and their use
CA2804173C (en) 2010-07-09 2015-01-13 Pfizer Limited Sulfonamide nav1.7 inhibitors
US9056865B2 (en) 2010-10-20 2015-06-16 Pfizer Inc. Pyridine-2-derivatives as smoothened receptor modulators
CN103298474B (zh) 2010-11-10 2016-06-29 ๆ— ้™่ฏๅ“่‚กไปฝๆœ‰้™ๅ…ฌๅธ ๆ‚็ŽฏๅŒ–ๅˆ็‰ฉๅŠๅ…ถ็”จ้€”
AR084824A1 (es) 2011-01-10 2013-06-26 Intellikine Inc Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas
AU2012212075A1 (en) 2011-02-02 2013-07-18 Amgen Inc. Methods and compositons relating to inhibition of IGF-1R
US9353127B2 (en) 2011-02-15 2016-05-31 Immunogen, Inc. Methods of preparation of conjugates
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
US20140178368A1 (en) 2011-04-19 2014-06-26 Leslie Lynne SHARP Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
CA2833935C (en) 2011-05-04 2020-09-15 Dhanapalan Nagarathnam Novel compounds as modulators of protein kinases
CA2842190A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PL3409278T3 (pl) 2011-07-21 2021-02-22 Sumitomo Pharma Oncology, Inc. Heterocykliczne inhibitory kinazy biaล‚kowej
RU2014111823A (ru) 2011-08-29 2015-10-10 ะ˜ะฝั„ะธะฝะธั‚ะธ ะคะฐั€ะผะฐััŒัŽั‚ะธะบะฐะปะท, ะ˜ะฝะบ. ะ“ะตั‚ะตั€ะพั†ะธะบะปะธั‡ะตัะบะธะต ัะพะตะดะธะฝะตะฝะธั ะธ ะธั… ะฟั€ะธะผะตะฝะตะฝะธั
JP5914667B2 (ja) 2011-09-22 2016-05-11 ใƒ•ใ‚กใ‚คใ‚ถใƒผใƒปใ‚คใƒณใ‚ฏ ใƒ”ใƒญใƒญใƒ”ใƒชใƒŸใ‚ธใƒณใŠใ‚ˆใณใƒ—ใƒชใƒณ่ช˜ๅฐŽไฝ“
WO2013049332A1 (en) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
ES2654160T3 (es) 2011-10-04 2018-02-12 Igem Therapeutics Limited Anticuerpos de IgE anti-HMW-MAA
RU2014114015A (ru) 2011-11-08 2015-12-20 ะŸั„ะฐะนะทะตั€ ะ˜ะฝะบ. ะกะฟะพัะพะฑั‹ ะปะตั‡ะตะฝะธั ะฒะพัะฟะฐะปะธั‚ะตะปัŒะฝั‹ั… ั€ะฐััั‚ั€ะพะนัั‚ะฒ ั ะธัะฟะพะปัŒะทะพะฒะฐะฝะธะตะผ ะฐะฝั‚ะธั‚ะตะป ะฟั€ะพั‚ะธะฒ m-csf
US9452215B2 (en) 2012-02-22 2016-09-27 The Regents Of The University Of Colorado Bourvadin derivatives and therapeutic uses thereof
EP3345624A1 (en) 2012-02-22 2018-07-11 The Regents Of The University Of Colorado Bouvardin derivatives and therapeutic uses thereof
KR102164317B1 (ko) 2012-03-30 2020-10-13 ๋ฆฌ์   ํŒŒ๋งˆ์Šˆํ‹ฐ์ปฌ์Šค ์†Œ์‹œ์—๋–ผ ์•„๋…ธ๋‹˜ C-met ๋‹จ๋ฐฑ์งˆ ํ‚ค๋‚˜์ œ์˜ ์กฐ์ ˆ์ œ๋กœ์„œ์˜ ์‹ ๊ทœํ•œ 3,5-๋””์น˜ํ™˜-3h-์ด๋ฏธ๋‹ค์กฐ[4,5-b]ํ”ผ๋ฆฌ๋”˜ ๋ฐ 3,5- ๋””์น˜ํ™˜ -3h-[1,2,3]ํŠธ๋ฆฌ์•„์กธ๋กœ[4,5-b] ํ”ผ๋ฆฌ๋”˜ ํ™”ํ•ฉ๋ฌผ
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3505534A1 (en) 2012-06-08 2019-07-03 Sutro Biopharma, Inc. Antibodies comprising sitespecific nonnatural amino acid residues, methods of their preparation and methods of their use
US9732161B2 (en) 2012-06-26 2017-08-15 Sutro Biopharma, Inc. Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
WO2014031566A1 (en) 2012-08-22 2014-02-27 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
PL3584255T3 (pl) 2012-08-31 2022-05-16 Sutro Biopharma, Inc. Modyfikowane aminokwasy zawierajฤ…ce grupฤ™ azydkowฤ…
ES2644758T3 (es) 2012-10-16 2017-11-30 Tolero Pharmaceuticals, Inc. Moduladores de PKM2 y mรฉtodos para su uso
LT2914296T (lt) 2012-11-01 2018-09-25 Infinity Pharmaceuticals, Inc. Vฤ—ลพio gydymas, panaudojant p13 kinazฤ—s izoformos moduliatorius
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014134486A2 (en) 2013-02-28 2014-09-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
US9999680B2 (en) 2013-02-28 2018-06-19 Immunogen, Inc. Conjugates comprising cell-binding agents and maytansinoids as cytotoxic agents
ES2738493T3 (es) 2013-03-14 2020-01-23 Tolero Pharmaceuticals Inc Inhibidores de JAK2 y ALK2 y mรฉtodos para su uso
JP2016512835A (ja) 2013-03-15 2016-05-09 ใ‚คใƒณใƒ†ใƒชใ‚ซใ‚คใƒณ๏ผŒ ใ‚จใƒซใ‚จใƒซใ‚ทใƒผ ใ‚ญใƒŠใƒผใ‚ผ้˜ปๅฎณๅ‰คใฎ็ต„ใฟๅˆใ‚ใ›ๅŠใณใใ‚Œใ‚‰ใฎไฝฟ็”จ
CA2904393A1 (en) 2013-03-15 2014-09-25 Araxes Pharma Llc Covalent inhibitors of kras g12c
WO2014151386A1 (en) 2013-03-15 2014-09-25 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9745319B2 (en) 2013-03-15 2017-08-29 Araxes Pharma Llc Irreversible covalent inhibitors of the GTPase K-Ras G12C
UY35464A (es) 2013-03-15 2014-10-31 Araxes Pharma Llc Inhibidores covalentes de kras g12c.
AU2014273946B2 (en) 2013-05-30 2020-03-12 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
US9764039B2 (en) 2013-07-10 2017-09-19 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
EP3363800A1 (en) 2013-10-03 2018-08-22 Kura Oncology, Inc. Heterocyclic inhibitors of erk and methods of use
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MY175778A (en) 2013-10-04 2020-07-08 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
EP3636639A1 (en) 2013-10-10 2020-04-15 Araxes Pharma LLC Inhibitors of kras g12c
TWI659021B (zh) 2013-10-10 2019-05-11 ไบž็‘žๅ…‹่ฅฟๆ–ฏ่ฃฝ่—ฅๅ…ฌๅธ ๏ผซ๏ฝ’๏ฝ๏ฝ“ ๏ฝ‡๏ผ‘๏ผ’๏ฝƒไน‹ๆŠ‘ๅˆถๅŠ‘
US9840493B2 (en) 2013-10-11 2017-12-12 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
WO2015061204A1 (en) 2013-10-21 2015-04-30 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
UA115388C2 (uk) 2013-11-21 2017-10-25 ะŸั„ะฐะนะทะตั€ ะ†ะฝะบ. 2,6-ะทะฐะผั–ั‰ะตะฝั– ะฟัƒั€ะธะฝะพะฒั– ะฟะพั…ั–ะดะฝั– ั‚ะฐ ั—ั… ะทะฐัั‚ะพััƒะฒะฐะฝะฝั ะฒ ะปั–ะบัƒะฒะฐะฝะฝั– ะฟั€ะพะปั–ั„ะตั€ะฐั‚ะธะฒะฝะธั… ะทะฐั…ะฒะพั€ัŽะฒะฐะฝัŒ
WO2015155624A1 (en) 2014-04-10 2015-10-15 Pfizer Inc. Dihydropyrrolopyrimidine derivatives
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
JP6574203B2 (ja) 2014-04-30 2019-09-11 ใƒ•ใ‚กใ‚คใ‚ถใƒผใƒปใ‚คใƒณใ‚ฏ ใ‚ทใ‚ฏใƒญใ‚ขใƒซใ‚ญใƒซ็ตๅˆใ‚ธใƒ˜ใƒ†ใƒญ็’ฐ่ช˜ๅฐŽไฝ“
AP2017009690A0 (en) 2014-06-19 2017-01-31 Ariad Pharma Inc Heteroaryl compounds for kinase inhibition
EP2957283B1 (de) 2014-06-19 2022-12-21 Symrise AG Verfahren zur Identifizierung von Medikamenten zur Beschleunigung der Wundheilung
WO2016001789A1 (en) 2014-06-30 2016-01-07 Pfizer Inc. Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
US10934360B2 (en) 2014-07-31 2021-03-02 The Hong Kong University Of Science And Technology Human monoclonal antibodies against EPHA4 and their use
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc ุนู„ุงุฌุงุช ู…ุฏู…ุฌุฉ ู„ู…ุนุงู„ุฌุฉ ุงู„ุณุฑุทุงู†
US10011600B2 (en) 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
WO2016049524A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3233829B1 (en) 2014-12-18 2019-08-14 Pfizer Inc Pyrimidine and triazine derivatives and their use as axl inhibitors
EA201792214A1 (ru) 2015-04-10 2018-01-31 ะั€ะฐะบัะธั ะคะฐั€ะผะฐ ะ›ะปะบ ะกะพะตะดะธะฝะตะฝะธั ะทะฐะผะตั‰ะตะฝะฝะพะณะพ ั…ะธะฝะฐะทะพะปะธะฝะฐ
JP6789239B2 (ja) 2015-04-15 2020-11-25 ใ‚ขใƒฉใ‚ฏใ‚ปใ‚น ใƒ•ใ‚กใƒผใƒž ใ‚จใƒซใ‚จใƒซใ‚ทใƒผ ๏ผซ๏ฝ’๏ฝ๏ฝ“ใฎ็ธฎๅˆไธ‰็’ฐ็ณปใ‚คใƒณใƒ’ใƒ“ใ‚ฟใƒผใŠใ‚ˆใณใใฎไฝฟ็”จใฎๆ–นๆณ•
WO2016172214A1 (en) 2015-04-20 2016-10-27 Tolero Pharmaceuticals, Inc. Predicting response to alvocidib by mitochondrial profiling
EP3288957A4 (en) 2015-05-01 2019-01-23 Cocrystal Pharma, Inc. NUCLEOSIDE ANALOGUE FOR THE TREATMENT OF VIRUSES OF THE FLAVIVIIDAE FAMILY AND CANCER
KR102608921B1 (ko) 2015-05-18 2023-12-01 ์Šค๋ฏธํ† ๋ชจ ํŒŒ๋งˆ ์˜จ์ฝœ๋กœ์ง€, ์ธํฌ. ์ƒ์ฒด ์ด์šฉ๋ฅ ์ด ์ฆ๊ฐ€๋œ ์•Œ๋ณด์‹œ๋”ฅ ํ”„๋กœ๋“œ๋Ÿฌ๊ทธ
TWI703150B (zh) 2015-06-04 2020-09-01 ็พŽๅ•†ๅบซๆ‹‰่…ซ็˜คๆŠ€่ก“่‚กไปฝๆœ‰้™ๅ…ฌๅธ ็”จๆ–ผๆŠ‘ๅˆถ๏ฝ๏ฝ…๏ฝŽ๏ฝ‰๏ฝŽๅŠ๏ฝ๏ฝŒ๏ฝŒ่›‹็™ฝไน‹ไบคไบ’ไฝœ็”จ็š„ๆ–นๆณ•ๅŠ็ต„ๅˆ็‰ฉ
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
KR20180034538A (ko) 2015-08-03 2018-04-04 ํ†จ๋ ˆ๋กœ ํŒŒ๋งˆ์ˆ˜ํ‹ฐ์ปฌ์Šค, ์ธํฌ. ์•”์˜ ์น˜๋ฃŒ๋ฅผ ์œ„ํ•œ ๋ณ‘ํ–‰ ์š”๋ฒ•
WO2017058902A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356354A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10858343B2 (en) 2015-09-28 2020-12-08 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058768A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10975071B2 (en) 2015-09-28 2021-04-13 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058792A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017070256A2 (en) 2015-10-19 2017-04-27 Araxes Pharma Llc Method for screening inhibitors of ras
AU2016355433C1 (en) 2015-11-16 2021-12-16 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
EA201891304A1 (ru) 2015-12-03 2019-01-31 ะะณะธะพั ะคะฐั€ะผะฐััŒัŽั‚ะธะบะฐะปั, ะ˜ะฝะบ. ะ˜ะะ“ะ˜ะ‘ะ˜ะขะžะ ะซ MAT2A ะ”ะ›ะฏ ะ›ะ•ะงะ•ะะ˜ะฏ MTAP-null ะ—ะ›ะžะšะะงะ•ะกะขะ’ะ•ะะะซะฅ ะžะŸะฃะฅะžะ›ะ•ะ™
US9988357B2 (en) 2015-12-09 2018-06-05 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
CA3011455A1 (en) 2016-01-27 2017-08-03 Sutro Biopharma, Inc. Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
PT3429591T (pt) 2016-03-16 2023-06-21 Univ Michigan Regents Derivados de tieno[2,3-d]pirimidina substituรญdos como inibidores de menina-llm e mรฉtodos de utilizaรงรฃo
TWI743096B (zh) 2016-03-16 2021-10-21 ็พŽๅ•†ๅบซๆ‹‰่…ซ็˜คๆŠ€่ก“่‚กไปฝๆœ‰้™ๅ…ฌๅธ Menin-mllไน‹ๆฉ‹่ฏ้›™็’ฐๆŠ‘ๅˆถๅŠ‘ๅŠไฝฟ็”จๆ–นๆณ•
US10822312B2 (en) 2016-03-30 2020-11-03 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
ES2910787T3 (es) 2016-05-12 2022-05-13 Univ Michigan Regents Inhibidores de ASH1L y mรฉtodos de tratamiento con los mismos
US11118233B2 (en) 2016-05-18 2021-09-14 The University Of Chicago BTK mutation and ibrutinib resistance
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
CA3035081A1 (en) 2016-09-02 2018-03-08 Dana-Farber Cancer Institute, Inc. Composition and methods of treating b cell disorders
US10280172B2 (en) 2016-09-29 2019-05-07 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
JP2019534260A (ja) 2016-10-07 2019-11-28 ใ‚ขใƒฉใ‚ฏใ‚ปใ‚น ใƒ•ใ‚กใƒผใƒž ใ‚จใƒซใ‚จใƒซใ‚ทใƒผ ๏ผฒ๏ฝ๏ฝ“ใฎ้˜ปๅฎณๅ‰คใจใ—ใฆใฎ่ค‡็ด ็’ฐๅผๅŒ–ๅˆ็‰ฉใŠใ‚ˆใณใใฎไฝฟ็”จๆ–นๆณ•
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
US10132797B2 (en) 2016-12-19 2018-11-20 Tolero Pharmaceuticals, Inc. Profiling peptides and methods for sensitivity profiling
BR112019012976A2 (pt) 2016-12-22 2019-12-31 Amgen Inc inibidores de kras g12c e mรฉtodos de uso dos mesmos
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
WO2018140513A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
CN110382483A (zh) 2017-01-26 2019-10-25 ไบš็‘žๅ…‹่ฅฟๆ–ฏๅˆถ่ฏๅ…ฌๅธ ็จ ๅˆ็š„n-ๆ‚็ŽฏๅŒ–ๅˆ็‰ฉๅŠๅ…ถไฝฟ็”จๆ–นๆณ•
AU2018213718B2 (en) 2017-01-26 2022-08-25 Zlip Holding Limited CD47 antigen binding unit and uses thereof
JP7327802B2 (ja) 2017-01-26 2023-08-16 ใ‚ขใƒฉใ‚ฏใ‚ปใ‚น ใƒ•ใ‚กใƒผใƒž ใ‚จใƒซใ‚จใƒซใ‚ทใƒผ ็ธฎๅˆใƒ˜ใƒ†ใƒญ๏ผใƒ˜ใƒ†ใƒญไบŒ็’ฐๅผๅŒ–ๅˆ็‰ฉใŠใ‚ˆใณใใฎไฝฟ็”จๆ–นๆณ•
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
CN110691779B (zh) 2017-03-24 2023-10-10 ๅบ“ๆ‹‰่‚ฟ็˜คๅญฆๅ…ฌๅธ ๆฒป็–—่ก€ๆถฒ***ๆถๆ€ง่‚ฟ็˜คๅ’Œๅฐคๅ› ่‚‰็˜ค็š„ๆ–นๆณ•
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc ู…ุซุจุทุงุช kras g12c ูˆุทุฑู‚ ู„ุงุณุชุฎุฏุงู…ู‡ุง
US11639346B2 (en) 2017-05-25 2023-05-02 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
JP2020521741A (ja) 2017-05-25 2020-07-27 ใ‚ขใƒฉใ‚ฏใ‚ปใ‚น ใƒ•ใ‚กใƒผใƒž ใ‚จใƒซใ‚จใƒซใ‚ทใƒผ ใŒใ‚“ใฎๅ‡ฆ็ฝฎใฎใŸใ‚ใฎๅŒ–ๅˆ็‰ฉใŠใ‚ˆใณใใฎไฝฟ็”จใฎๆ–นๆณ•
KR20200010306A (ko) 2017-05-25 2020-01-30 ์•„๋ฝ์„ธ์Šค ํŒŒ๋งˆ ์—˜์—˜์”จ Kras์˜ ๊ณต์œ ์  ์–ต์ œ์ œ
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
US20200207859A1 (en) 2017-07-26 2020-07-02 Sutro Biopharma, Inc. Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
SG11202001499WA (en) 2017-09-08 2020-03-30 Amgen Inc Inhibitors of kras g12c and methods of using the same
US11497756B2 (en) 2017-09-12 2022-11-15 Sumitomo Pharma Oncology, Inc. Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
EP3684814A1 (en) 2017-09-18 2020-07-29 Sutro Biopharma, Inc. Anti-folate receptor alpha antibody conjugates and their uses
TW201920170A (zh) 2017-09-20 2019-06-01 ็พŽๅ•†ๅบซๆ‹‰่…ซ็˜คๆŠ€่ก“่‚กไปฝๆœ‰้™ๅ…ฌๅธ ็ถ“ๅ–ไปฃไน‹menin-mll ๆŠ‘ๅˆถๅŠ‘ๅŠไฝฟ็”จๆ–นๆณ•
WO2019075367A1 (en) 2017-10-13 2019-04-18 Tolero Pharmaceuticals, Inc. PKM2 ACTIVATORS IN COMBINATION WITH OXYGEN REACTIVE SPECIES FOR THE TREATMENT OF CANCER
CN111655257A (zh) 2017-11-10 2020-09-11 ๅฏ†ๆญ‡ๆ นๅคงๅญฆ่‘ฃไบ‹ไผš Ash1lๆŠ‘ๅˆถๅ‰‚ๅŠ็”จๅ…ถ่ฟ›่กŒๆฒป็–—็š„ๆ–นๆณ•
CA3084809A1 (en) 2017-12-07 2019-06-13 The Regents Of The University Of Michigan Nsd family inhibitors and methods of treatment therewith
US11013741B1 (en) 2018-04-05 2021-05-25 Sumitomo Dainippon Pharma Oncology, Inc. AXL kinase inhibitors and use of the same
AU2019262589B2 (en) 2018-05-04 2022-07-07 Amgen Inc. KRAS G12C inhibitors and methods of using the same
EP3788053A1 (en) 2018-05-04 2021-03-10 Amgen Inc. Kras g12c inhibitors and methods of using the same
JP7361720B2 (ja) 2018-05-10 2023-10-16 ใ‚ขใƒ ใ‚ธใ‚จใƒณใƒปใ‚คใƒณใ‚ณใƒผใƒใƒฌใƒผใƒ†ใƒ„ใƒ‰ ใŒใ‚“ใฎๆฒป็™‚ใฎใŸใ‚ใฎ๏ฝ‹๏ฝ’๏ฝ๏ฝ“ ๏ฝ‡๏ผ‘๏ผ’๏ฝƒ้˜ปๅฎณๅ‰ค
US11096939B2 (en) 2018-06-01 2021-08-24 Amgen Inc. KRAS G12C inhibitors and methods of using the same
US11319302B2 (en) 2018-06-07 2022-05-03 The Regents Of The University Of Michigan PRC1 inhibitors and methods of treatment therewith
MX2020012204A (es) 2018-06-11 2021-03-31 Amgen Inc Inhibidores de kras g12c para tratar el cรกncer.
MX2020012261A (es) 2018-06-12 2021-03-31 Amgen Inc Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer.
CA3103995A1 (en) 2018-07-26 2020-01-30 Sumitomo Dainippon Pharma Oncology, Inc. Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
MX2021000887A (es) 2018-08-01 2021-03-31 Araxes Pharma Llc Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
WO2020060944A1 (en) 2018-09-17 2020-03-26 Sutro Biopharma, Inc. Combination therapies with anti-folate receptor antibody conjugates
US20210380595A1 (en) 2018-10-24 2021-12-09 Araxes Pharma Llc 2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-6-(1h-indazol-4-yl)-benzonitrile derivatives and related compounds as inhibitors of g12c mutant kras protein for inhibiting tumor metastasis
JP2020090482A (ja) 2018-11-16 2020-06-11 ใ‚ขใƒ ใ‚ธใ‚จใƒณใƒปใ‚คใƒณใ‚ณใƒผใƒใƒฌใƒผใƒ†ใƒ„ใƒ‰ ๏ผซ๏ฝ’๏ฝ๏ฝ“ ๏ฝ‡๏ผ‘๏ผ’๏ฝƒ้˜ปๅฎณๅ‰คๅŒ–ๅˆ็‰ฉใฎ้‡่ฆใชไธญ้–“ไฝ“ใฎๆ”น่‰ฏๅˆๆˆๆณ•
JP7377679B2 (ja) 2018-11-19 2023-11-10 ใ‚ขใƒ ใ‚ธใ‚จใƒณใƒปใ‚คใƒณใ‚ณใƒผใƒใƒฌใƒผใƒ†ใƒ„ใƒ‰ ใŒใ‚“ๆฒป็™‚ใฎใŸใ‚ใฎ๏ฝ‹๏ฝ’๏ฝ๏ฝ“๏ฝ‡๏ผ‘๏ผ’๏ฝƒ้˜ปๅฎณๅ‰คๅŠใณ๏ผ‘็จฎไปฅไธŠใฎ่–ฌๅญฆ็š„ใซๆดปๆ€งใช่ฟฝๅŠ ใฎ่–ฌๅ‰คใ‚’ๅซใ‚€ไฝต็”จ็™‚ๆณ•
MA55136A (fr) 2018-11-19 2022-02-23 Amgen Inc Inhibiteurs de kras g12c et leurs procรฉdรฉs d'utilisation
CA3120383A1 (en) 2018-11-29 2020-06-04 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer
EP3890749A4 (en) 2018-12-04 2022-08-03 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 INHIBITORS AND POLYMORPHS THEREOF FOR USE AS CANCER TREATMENT AGENT
CA3123044A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
JOP20210154B1 (ar) 2018-12-20 2023-09-17 Amgen Inc ู…ุซุจุทุงุช kif18a
CA3123227A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
WO2020132651A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Kif18a inhibitors
WO2020167990A1 (en) 2019-02-12 2020-08-20 Tolero Pharmaceuticals, Inc. Formulations comprising heterocyclic protein kinase inhibitors
US20230096028A1 (en) 2019-03-01 2023-03-30 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
US20230148450A9 (en) 2019-03-01 2023-05-11 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
JP2022525149A (ja) 2019-03-20 2022-05-11 ใ‚นใƒŸใƒˆใƒข ใƒ€ใ‚คใƒ‹ใƒƒใƒใƒณ ใƒ•ใ‚กใƒผใƒž ใ‚ชใƒณใ‚ณใƒญใ‚ธใƒผ๏ผŒ ใ‚คใƒณใ‚ณใƒผใƒใƒฌใ‚คใƒ†ใƒƒใƒ‰ ใƒ™ใƒใƒˆใ‚ฏใƒฉใ‚ฏใ‚นใŒๅคฑๆ•—ใ—ใŸๆ€ฅๆ€ง้ชจ้ซ„ๆ€ง็™ฝ่ก€็—…๏ผˆ๏ฝ๏ฝ๏ฝŒ๏ผ‰ใฎๅ‡ฆ็ฝฎ
EP3941463A1 (en) 2019-03-22 2022-01-26 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprising pkm2 modulators and methods of treatment using the same
US20220362394A1 (en) 2019-05-03 2022-11-17 Sutro Biopharma, Inc. Anti-bcma antibody conjugates
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
CR20210665A (es) 2019-05-21 2022-01-25 Amgen Inc Formas en estado sรณlido
WO2021003417A1 (en) 2019-07-03 2021-01-07 Sumitomo Dainippon Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
US20220281843A1 (en) 2019-08-02 2022-09-08 Amgen Inc. Kif18a inhibitors
CA3146693A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
CN114391012A (zh) 2019-08-02 2022-04-22 ็พŽๅ›ฝๅฎ‰่ฟ›ๅ…ฌๅธ ไฝœไธบkif18aๆŠ‘ๅˆถๅ‰‚็š„ๅกๅ•ถ่ก็”Ÿ็‰ฉ
JP2022542319A (ja) 2019-08-02 2022-09-30 ใ‚ขใƒ ใ‚ธใ‚จใƒณใƒปใ‚คใƒณใ‚ณใƒผใƒใƒฌใƒผใƒ†ใƒ„ใƒ‰ ๏ผซ๏ฝ‰๏ฝ†๏ผ‘๏ผ˜๏ฝ้˜ปๅฎณๅ‰ค
TW202126636A (zh) 2019-09-30 2021-07-16 ็พŽๅ•†้˜ฟๅ‰ๆญๆ–ฏ่ฃฝ่—ฅๅ…ฌๅธ ไฝœ็‚บ๏ฝ๏ฝ…๏ฝŽ๏ฝ‰๏ฝŽๆŠ‘ๅˆถๅŠ‘ไน‹ๅ…ญๆฐซๅกๅ•ถๅŒ–ๅˆ็‰ฉ
EP4048671A1 (en) 2019-10-24 2022-08-31 Amgen Inc. Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
AU2020372881A1 (en) 2019-10-28 2022-06-09 Merck Sharp & Dohme Llc Small molecule inhibitors of KRAS G12C mutant
CN115551500A (zh) 2019-10-31 2022-12-30 ๅคง้น่ฏๅ“ๅทฅไธšๆ ชๅผไผš็คพ 4-ๆฐจๅŸบไธ-2-็ƒฏ้…ฐ่ƒบ่ก็”Ÿ็‰ฉๅŠๅ…ถ็›
MX2022005360A (es) 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
AU2020379731A1 (en) 2019-11-04 2022-05-05 Revolution Medicines, Inc. Ras inhibitors
WO2021091982A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
CN116425742A (zh) 2019-11-08 2023-07-14 ้”ๆ–ฐๅŒป่ฏๅ…ฌๅธ ๅŒ็Žฏๆ‚่ŠณๅŸบๅŒ–ๅˆ็‰ฉๅŠๅ…ถ็”จ้€”
WO2021097207A1 (en) 2019-11-14 2021-05-20 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
BR112022009390A2 (pt) 2019-11-14 2022-08-09 Amgen Inc Sรญntese melhorada de composto inibidor de kras g12c
WO2021108683A1 (en) 2019-11-27 2021-06-03 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
EP4087611A1 (en) 2020-01-07 2022-11-16 Revolution Medicines, Inc. Shp2 inhibitor dosing and methods of treating cancer
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof
EP4114852A1 (en) 2020-03-03 2023-01-11 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
TW202204333A (zh) 2020-04-08 2022-02-01 ็พŽๅ•†้˜ฟๅ‰ๆญๆ–ฏ่ฃฝ่—ฅๅ…ฌๅธ MeninๆŠ‘ๅˆถๅŠ‘ๅŠๆฒป็™‚็™Œ็—‡ไน‹ไฝฟ็”จๆ–นๆณ•
TW202204334A (zh) 2020-04-08 2022-02-01 ็พŽๅ•†้˜ฟๅ‰ๆญๆ–ฏ่ฃฝ่—ฅๅ…ฌๅธ MeninๆŠ‘ๅˆถๅŠ‘ๅŠๆฒป็™‚็™Œ็—‡ไน‹ไฝฟ็”จๆ–นๆณ•
EP4139299A1 (en) 2020-04-24 2023-03-01 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
WO2021215545A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
EP4168002A1 (en) 2020-06-18 2023-04-26 Revolution Medicines, Inc. Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
JP2023533982A (ja) 2020-07-10 2023-08-07 ใ‚ถ ใƒชใƒผใ‚ธใ‚งใƒณใƒ„ ใ‚ชใƒ– ใ‚ถ ใƒฆใƒ‹ใƒใƒผใ‚ทใƒ†ใ‚ฃ ใ‚ชใƒ– ใƒŸใ‚ทใ‚ฌใƒณ ๏ผง๏ฝ๏ฝ“๏ผ”๏ผ‘้˜ปๅฎณๅ‰คๅŠใณใใฎไฝฟ็”จๆ–นๆณ•
TW202216151A (zh) 2020-07-15 2022-05-01 ๆ—ฅๅ•†ๅคง้ตฌ่—ฅๅ“ๅทฅๆฅญ่‚กไปฝๆœ‰้™ๅ…ฌๅธ ๅซๆœ‰ไฝฟ็”จๆ–ผ่…ซ็˜คไน‹ๆฒป็™‚ไน‹ๅ˜งๅ•ถๅŒ–ๅˆ็‰ฉไน‹็ต„ๅˆ
KR20230081726A (ko) 2020-09-03 2023-06-07 ๋ ˆ๋ณผ๋ฃจ์…˜ ๋ฉ”๋””์Šจ์ฆˆ, ์ธํฌ. Shp2 ๋Œ์—ฐ๋ณ€์ด๊ฐ€ ์žˆ๋Š” ์•…์„ฑ ์ข…์–‘์„ ์น˜๋ฃŒํ•˜๊ธฐ ์œ„ํ•œ sos1 ์–ต์ œ์ œ์˜ ์šฉ๋„
CN117683049A (zh) 2020-09-15 2024-03-12 ้”ๆ–ฐๅŒป่ฏๅ…ฌๅธ ไฝœไธบrasๆŠ‘ๅˆถๅ‰‚ไปฅๆฒป็–—็™Œ็—‡็š„ๅฒๅ“š่ก็”Ÿ็‰ฉ
WO2022111793A1 (en) 2020-11-24 2022-06-02 Symrise Ag Medicament for accelerated wound healing
TW202237119A (zh) 2020-12-10 2022-10-01 ็พŽๅ•†ไฝๅ‹่ฃฝ่—ฅ่…ซ็˜คๅ…ฌๅธ ๏ผก๏ฝŒ๏ฝ‹๏น˜๏ผ•ๆŠ‘ๅˆถๅŠ‘ๅ’Œๅฝผไน‹็”จ้€”
JP2024501280A (ja) 2020-12-22 2024-01-11 ใ‚ญใƒซใƒปใƒฌใ‚ฌใƒผใƒปใ‚ปใƒฉใƒ”ใƒฅใƒผใƒ†ใ‚ฃใ‚ฏใ‚นใƒปใ‚คใƒณใ‚ณใƒผใƒใƒฌใƒผใƒ†ใƒƒใƒ‰ ๏ผณ๏ฝ๏ฝ“๏ผ‘้˜ปๅฎณๅ‰คใŠใ‚ˆใณใใฎไฝฟ็”จ
WO2022161593A1 (en) 2021-01-26 2022-08-04 Symrise Ag Medicament for accelerated wound healing
KR20230170039A (ko) 2021-04-13 2023-12-18 ๋‰ด๋ฒ ์ผ๋ŸฐํŠธ, ์•„์ด์—”์”จ. Egfr ๋Œ์—ฐ๋ณ€์ด๋ฅผ ์ง€๋‹ˆ๋Š” ์•”์„ ์น˜๋ฃŒํ•˜๊ธฐ ์œ„ํ•œ ์•„๋ฏธ๋…ธ-์น˜ํ™˜๋œ ํ—คํ…Œ๋กœ์‚ฌ์ดํด
KR20240004659A (ko) 2021-04-30 2024-01-11 ์…€์ง„ ์ฝ”ํฌ๋ ˆ์ด์…˜ ๊ฐ๋งˆ ์„ธํฌ๋ ˆํƒ€์ œ ์–ต์ œ์ œ(gsi)์™€ ๋ณ‘์šฉํ•˜์—ฌ ํ•ญ-bcma ํ•ญ์ฒด-์•ฝ๋ฌผ ์ ‘ํ•ฉ์ฒด(adc)๋ฅผ ์‚ฌ์šฉํ•˜๋Š” ๋ณ‘์šฉ ์š”๋ฒ•
KR20240017811A (ko) 2021-05-05 2024-02-08 ๋ ˆ๋ณผ๋ฃจ์…˜ ๋ฉ”๋””์Šจ์ฆˆ, ์ธํฌ. ์•”์˜ ์น˜๋ฃŒ๋ฅผ ์œ„ํ•œ ras ์–ต์ œ์ œ
US20230106174A1 (en) 2021-05-05 2023-04-06 Revolution Medicines, Inc. Ras inhibitors
CN117500811A (zh) 2021-05-05 2024-02-02 ้”ๆ–ฐๅŒป่ฏๅ…ฌๅธ ๅ…ฑไปทrasๆŠ‘ๅˆถๅ‰‚ๅŠๅ…ถ็”จ้€”
WO2022250170A1 (en) 2021-05-28 2022-12-01 Taiho Pharmaceutical Co., Ltd. Small molecule inhibitors of kras mutated proteins
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023056589A1 (en) 2021-10-08 2023-04-13 Servier Pharmaceuticals Llc Menin inhibitors and methods of use for treating cancer
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023211812A1 (en) 2022-04-25 2023-11-02 Nested Therapeutics, Inc. Heterocyclic derivatives as mitogen-activated protein kinase (mek) inhibitors
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
US20240058465A1 (en) 2022-06-30 2024-02-22 Sutro Biopharma, Inc. Anti-ror1 antibody conjugates, compositions comprising anti ror1 antibody conjugates, and methods of making and using anti-ror1 antibody conjugates
WO2024010925A2 (en) 2022-07-08 2024-01-11 Nested Therapeutics, Inc. Mitogen-activated protein kinase (mek) inhibitors

Family Cites Families (1)

* Cited by examiner, โ€  Cited by third party
Publication number Priority date Publication date Assignee Title
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids

Also Published As

Publication number Publication date
BG104917A (en) 2001-06-29
DZ2753A1 (fr) 2005-09-15
SK284154B6 (sk) 2004-10-05
AU758701B2 (en) 2003-03-27
PL343518A1 (en) 2001-08-27
MY132929A (en) 2007-10-31
WO1999052889A1 (en) 1999-10-21
EP1070058B1 (en) 2003-05-02
DE69907435D1 (de) 2003-06-05
OA11498A (en) 2004-05-07
GT199900043A (es) 2000-09-14
HUP0101613A2 (hu) 2001-12-28
EA004227B1 (ru) 2004-02-26
IS5619A (is) 2000-09-08
PA8469501A1 (es) 2000-09-29
KR100430183B1 (ko) 2004-05-03
ATE239005T1 (de) 2003-05-15
KR20010042601A (ko) 2001-05-25
UA55526C2 (uk) 2003-04-15
NZ506806A (en) 2002-11-26
CO5050369A1 (es) 2001-06-27
CN1296481A (zh) 2001-05-23
AU3271099A (en) 1999-11-01
AP9901505A0 (en) 1999-06-30
ID26222A (id) 2000-12-07
PT1070058E (pt) 2003-07-31
TNSN99053A1 (fr) 2005-11-10
EP1070058A1 (en) 2001-01-24
EA200000919A1 (ru) 2001-02-26
AR019263A1 (es) 2002-02-13
ES2192397T3 (es) 2003-10-01
NO20005076L (no) 2000-12-07
HUP0101613A3 (en) 2003-01-28
DE69907435T2 (de) 2003-11-20
PE20000414A1 (es) 2000-05-24
DK1070058T3 (da) 2003-08-18
CZ20003737A3 (cs) 2001-09-12
SK14892000A3 (sk) 2002-03-05
CA2327758A1 (en) 1999-10-21
AP968A (en) 2001-05-29
SA99200091A (ar) 2005-12-03
MA24832A1 (fr) 1999-12-31
HRP20000648A2 (en) 2000-12-31
JP3660873B2 (ja) 2005-06-15
ZA992629B (en) 2000-10-09
YU57500A (sh) 2003-10-31
CA2327758C (en) 2006-01-10
US6087392A (en) 2000-07-11
JP2002511458A (ja) 2002-04-16
NO20005076D0 (no) 2000-10-09
TR200002951T2 (tr) 2001-01-22
BR9909562A (pt) 2000-12-19

Similar Documents

Publication Publication Date Title
IL138637A0 (en) (4-arylsulfonylamino) tetrahydropyran-4- carboxylic acid hydroxamides
IL139470A0 (en) Oxyiminoalkanoic acid derivatives
IL139636A0 (en) New 3-aryl-2-hydroxypropionic acid derivative (i)
PL334997A1 (en) Derivatives or arylosulphonyl-hydroxamic acid
PL341642A1 (en) Novel macrolydes
HK1035525A1 (en) Aminomethylcarboxylic acid derivatives
HRP20000529B1 (en) Novel dihydroxyhexanoic acid derivatives
GB2335669B (en) Structural truss
EP1068213A4 (en) SILOXANES WITH AMINO-ORGANIC FUNCTIONAL GROUP
GB9816729D0 (en) Substituted cyclohexylaminopyrimidines
HK1039937A1 (zh) ๅ–ไปฃ็š„3-็กซไปฃๆฐจๅŸบ็”ฒ้…ฐๅŸบๅกๅ”‘้กžๅŒ–ๅˆ็‰ฉ
PL347397A1 (en) Substituted 3-aryl-pyrazoles
PL345866A1 (en) Substituted cyclooctadepsipeptides
HK1039335A1 (zh) ๅ–ไปฃ็š„่‹ฏ็”ฒ้…ฐๅŸบ็’ฐๅทฒไบŒ้…ฎ้กžๅŒ–ๅˆ็‰ฉ
GB2335259B (en) An explosion-suppressing structure
GB9903377D0 (en) Amphibious-tricycle (amphi-trike)
SI1070058T1 (en) (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides
GB2336859B (en) Structural truss
GB9804647D0 (en) Epiwarn (electro-encepalo-feedback)
SI1084103T1 (en) New 3-aryl-2-hydroxypropionic acid derivative (i)
GB9813572D0 (en) Solution
GB9805049D0 (en) Solution
AU2738299A (en) Solution
PL327867A1 (en) Truss
GB9802802D0 (en) Framing solution